Proof of Usefulness Report

DCN Dx

Analysis completed on 2/6/2026

+669
Proof of Usefulness Score
Category Standard

DCN Dx is a well-established, private equity-backed Contract Development and Manufacturing Organization (CDMO) in the diagnostics space with estimated annual revenue between $15M-$20M and ~100 employees (contrary to the submitted 350). While the submission contained inaccuracies (claiming 'everyone' as the audience and a confusing 'marketcap' figure), the underlying business has high real-world utility, verified traction through acquisitions (PortaScience, Biomed Diagnostics), and institutional backing (Martis Capital). The score reflects the strong business fundamentals despite the low-quality submission data.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+90.0
Audience Reach Impact+40.0
Technical Innovation+80.0
Evidence Of Traction+85.0
Market Timing Relevance+85.0
Functional Completeness+10.0
Subtotal+727.5
Usefulness Multiplierx0.92
Final Score+669

Project Details

Project URL
Description
DCN Dx specializes in the contract development of rapid point of care tests. We offer a variety of services and products that assist our clients in the design and development of user-centric, high performing diagnostic devices. Contract development of rapid immunoassays is at the core of all that we do at DCN Dx. We focus on lateral flow, flow through, and microfuidic formats. Our staff has unparalleled experience in developing assays with tough specifications, regarding high sensitivity, quantification, multiplexing and reader integration. Our ISO 9001:2015 compliant development process allows for close integration of assay and device development pathways, which ensures the best chance of commercial success for the product. As well as developing the assay itself, DCN Dx's integrated engineering team will design, develop and integrate your entire device. The engineers work closely with our scientists to create cassettes and sample handling devices that enhance the performance of your assay and meet all end-user specifications. We deliver the product, not just the parts. DCN Dx also offers a variety of products and services to assist our clients at any stage of development, including: - Custom, private education and training courses in lateral flow technology, during which we teach the details of how to develop and manufacture rapid assays. - Consulting services to assist with any aspect of rapid assay development, manufacturing, regulation and commercialization. - Custom protein-protein, protein-particle, small molecule-protein and small molecule- particle conjugations. - Lateral flow material starter kits, conjugation kits, reagents, cassettes and materials for use during rapid assay development. DCN Dx represents a single source that can help you manage and deliver completely validated assay platforms. CONTACT US: www.dcndx.com info@dcndx.com (760) 804-3886

Algorithm Insights

Market Position
Strong market validation with clear user adoption patterns
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline